Your browser doesn't support javascript.
loading
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer, Paula; Tausch, Eugen; von Tresckow, Julia; Giza, Adam; Robrecht, Sandra; Schneider, Christof; Fürstenau, Moritz; Langerbeins, Petra; Al-Sawaf, Othman; Pelzer, Benedikt W; Fink, Anna Maria; Fischer, Kirsten; Wendtner, Clemens-Martin; Eichhorst, Barbara; Kneba, Michael; Stilgenbauer, Stephan; Hallek, Michael.
Afiliação
  • Cramer P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Tausch E; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
  • von Tresckow J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Giza A; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
  • Robrecht S; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Schneider C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Langerbeins P; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
  • Al-Sawaf O; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Pelzer BW; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Wendtner CM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Kneba M; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany; and.
  • Stilgenbauer S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Hallek M; Department of Internal Medicine II, University of Schleswig-Holstein, Kiel, Germany.
Blood ; 138(19): 1805-1816, 2021 11 11.
Article em En | MEDLINE | ID: mdl-34086865
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Sulfonamidas / Adenina / Leucemia Linfocítica Crônica de Células B / Proteína Supressora de Tumor p53 / Compostos Bicíclicos Heterocíclicos com Pontes / Anticorpos Monoclonais Humanizados / Cloridrato de Bendamustina Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Sulfonamidas / Adenina / Leucemia Linfocítica Crônica de Células B / Proteína Supressora de Tumor p53 / Compostos Bicíclicos Heterocíclicos com Pontes / Anticorpos Monoclonais Humanizados / Cloridrato de Bendamustina Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha